--- title: "Alumis | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 1.662 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295844490.md" datetime: "2026-08-13T20:43:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295844490.md) - [en](https://longbridge.com/en/news/295844490.md) - [zh-HK](https://longbridge.com/zh-HK/news/295844490.md) --- # Alumis | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 1.662 M Revenue: As of FY2026 Q2, the actual value is USD 1.662 M, missing the estimate of USD 3.468 M. EBIT: As of FY2026 Q2, the actual value is USD -148.86 M. #### Cash, Cash Equivalents, and Marketable Securities Alumis Inc. reported $502.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, an increase from $308.5 million as of December 31, 2025. #### Revenue - **Collaboration Revenue**: For the three months ended June 30, 2026, collaboration revenue was $1.7 million, decreasing from $2.7 million for the same period in 2025. For the six months ended June 30, 2026, collaboration revenue was $3.4 million, up from $2.7 million for the same period in 2025. - **License Revenue**: For the six months ended June 30, 2025, license revenue was $17.4 million, with no license revenue reported for the same period in 2026. - **Total Revenue**: Total revenue for the three months ended June 30, 2026, was $1.7 million, down from $2.7 million in the prior year period. For the six months ended June 30, 2026, total revenue was $3.4 million, a decrease from $20.1 million for the same period in 2025. #### Operating Expenses - **Research and Development (R&D) Expenses**: R&D expenses were $85.3 million for the three months ended June 30, 2026, a decrease from $108.8 million for the same period in 2025, primarily due to lower clinical trial and contract research costs and severance costs from the merger with ACELYRIN, Inc., partially offset by increased costs for the Phase 3 ONWARD3 clinical trial and personnel-related expenses. For the six months ended June 30, 2026, R&D expenses were $166.9 million, down from $205.4 million for the same period in 2025. - **General and Administrative (G&A) Expenses**: G&A expenses were $23.4 million for the three months ended June 30, 2026, compared to $34.5 million for the same period in 2025, mainly due to severance and transaction costs related to the merger with ACELYRIN, Inc., partially offset by legal expenses and increased personnel-related expenses. For the six months ended June 30, 2026, G&A expenses were $42.0 million, compared to $56.7 million for the same period in 2025. - **Intangible Assets Impairment Loss**: Operating expenses for the three and six months ended June 30, 2026, included a $41.8 million impairment loss related to the acquired IPR&D intangible asset associated with the lonigutamab program. #### Operating Loss Loss from operations was - $148.9 million for the three months ended June 30, 2026, compared to - $140.5 million for the same period in 2025. For the six months ended June 30, 2026, loss from operations was - $247.3 million, compared to - $242.1 million for the same period in 2025. #### Other Income (Expense) - **Gain on Bargain Purchase**: A non-operating gain of $187.9 million was recorded for the three and six months ended June 30, 2025, related to the merger with ACELYRIN, Inc. - **Interest Income**: Interest income increased to $4.9 million for the three months ended June 30, 2026, from $3.4 million in the prior year period. For the six months ended June 30, 2026, interest income was $10.3 million, up from $6.0 million for the same period in 2025. #### Net Income (Loss) Alumis Inc. reported a net loss of - $142.2 million for the three months ended June 30, 2026, compared to net income of $59.3 million for the same period in 2025, which included the non-operating gain. For the six months ended June 30, 2026, net loss was - $235.3 million, compared to - $39.6 million for the same period in 2025. #### Total Comprehensive Income (Loss) Total comprehensive loss was - $142.4 million for the three months ended June 30, 2026, compared to total comprehensive income of $59.4 million for the same period in 2025. For the six months ended June 30, 2026, total comprehensive loss was - $236.1 million, compared to - $39.7 million for the same period in 2025. #### Operational Metrics and Recent Achievements - **Envudeucitinib (Plaque Psoriasis - PsO)**: Topline results from the ONWARD3 long-term extension study showed 75% and 54% of patients achieved PASI 90 and PASI 100, respectively, after up to 48 weeks of continuous treatment with a consistent safety profile. Alumis Inc. is on track to submit its New Drug Application (NDA) to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. - **Envudeucitinib (Systemic Lupus Erythematosus - SLE)**: Alumis Inc. anticipates potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE in the third quarter of 2026. - **TYK2 Franchise and Pipeline**: Alumis Inc. is prioritizing Sjögren’s disease and cutaneous lupus erythematosus (CLE) as additional indications for envudeucitinib, contingent on LUMUS Phase 2b results and capital allocation. A Phase 2 biomarker trial for A-005, a central nervous system penetrant TYK2 inhibitor, in Parkinson’s disease patients is planned for initiation in the first half of 2027. - **Lonigutamab Program**: Alumis Inc. completed a strategic review of the lonigutamab program and decided to explore strategic alternatives for this asset. #### Financial Guidance and Outlook Alumis Inc. expects its existing cash, cash equivalents, and marketable securities as of June 30, 2026, to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027. Key milestones include the NDA submission for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026 and potentially pivotal Phase 2b SLE topline data in Q3 2026. The company also plans to initiate a Phase 2 biomarker trial for A-005 in Parkinson’s disease in the first half of 2027. ### Related Stocks - [ALMS.US](https://longbridge.com/en/quote/ALMS.US.md) ## Related News & Research - [Alumis says envudeucitinib hits 54% PASI 100 at 48 weeks in ONWARD3 plaque psoriasis extension study](https://longbridge.com/en/news/295445123.md) - [Rocket Companies director Sarah Watterson files Form 3 initial beneficial ownership statement](https://longbridge.com/en/news/296141298.md) - [Apollo Global Management files Form 3 initial beneficial ownership statement for LDB 2025 LLC](https://longbridge.com/en/news/295974245.md) - [Xylem files Form 3 initial beneficial ownership statement for director D. Christian Koch](https://longbridge.com/en/news/295840807.md) - [Bausch + Lomb files Form 3 disclosing director Thomas Appio stake of 27,583 shares](https://longbridge.com/en/news/295977890.md)